Study Uncovers Immune Trigger Behind Vaccine-induced Immune Thrombocytopenia And Thrombosis

A world investigation collaboration of scientists from McMaster University (Canada), Flinders University (Australia) and Universitätsmedizin Greifswald (Germany) uncovered why a mini number of group developed vulnerable humor clots aft either receiving definite COVID‑19 vaccines aliases experiencing a earthy adenovirus infection, and nan reply lies successful an unexpected lawsuit of misdirected targeting by nan immune system.

The discovery, published Feb. 12, 2026 successful nan New England Journal of Medicine, explains really and why nan assemblage occasionally generates vulnerable antibodies against its ain humor proteins causing vaccine-induced immune thrombocytopenia and thrombosis (VITT). Specifically, nan study identifies nan nonstop viral constituent that can, successful uncommon circumstances, trigger this immune misdirection. Further, nan study identifies a caller system by which an immune guidance tin spell wrong, giving scientists a roadmap for explaining different rare, antibody-driven adverse reactions to definite infections, medications, aliases biology exposures.

This study shows, pinch molecular precision, really a normal immune consequence to an adenovirus tin very seldom spell off‑track. By identifying nan nonstop viral macromolecule progressive and nan circumstantial antibody alteration that drives this misdirection, we now understand not only what happens successful VITT but why."

Theodore Warkentin, corresponding writer of nan study and professor emeritus, Department of Pathology & Molecular Medicine, McMaster University

"What's breathtaking is that we tin now constituent to a circumstantial viral constituent that tin beryllium redesigned. It intends early adenoviral vaccines tin support each their advantages while sidestepping nan uncommon immune misfire that causes VITT," he adds.

The discovery

The researchers recovered that VITT tin hap aft a repetition vulnerability to adenovirus, whether from a vaccine aliases a earthy infection, but only successful group who person a definite inherited type of an antibody cistron (IGLV3‑21*02 aliases *03). Because this cistron version is recovered successful up to 60 per cent of nan population, it cannot by itself relationship for nan ultrarare complication.

However, nan immune consequence that sets nan shape for VITT is aimed astatine an adenovirus macromolecule called macromolecule VII (pVII), which happens to intimately lucifer a region of a quality humor protein, platelet facet 4 (PF4). In very uncommon cases, while nan immune strategy is responding to pVII, a single, circumstantial mutation tin originate successful 1 of nan antibody‑producing cells. That mutation (called K31E) changes conscionable 1 positively-charged amino acerb to a negatively-charged amino acid, and that mini displacement is capable to redirect nan antibody targeting distant from pVII and toward PF4 instead. Once nan antibody binds PF4, it activates platelets and triggers nan clotting and debased platelet counts seen successful VITT.

Crucially, nan study detected this aforesaid K31E mutation successful each VITT diligent antibodies examined. When researchers reversed nan mutation successful lab‑engineered antibodies, their vulnerable activity disappeared, proving that this circumstantial alteration is required for nan complication to occur.

The squad uncovered nan system utilizing cutting‑edge tools: they sequenced antibodies from patients pinch VITT, mapped their structures pinch wide spectrometry, and engineered laboratory versions to watch really they behaved and mutated. They besides confirmed nan findings successful a humanized rodent model, wherever nan VITT antibody caused clotting, but nan "back‑mutated" type did not.

"Many group cognize that mutations successful DNA explicate things for illustration congenital abnormalities aliases cancer, but to person an immune compartment that is making its expected antibodies triggered by a microorganism abruptly alteration its reactivity against a self-protein owed to a circumstantial mutation is simply a spectacular uncovering that is unprecedented successful nan technological literature," says Warkentin.

Why it matters

This find answers 5 long‑standing questions astir VITT:

1. why adenoviral‑vector vaccines - and earthy adenovirus infection - tin trigger it
2. why PF4 is nan target (mimicry betwixt pVII and PF4)
3. why VITT is extraordinarily uncommon (it requires a specific, chance mutation successful a predisposed person);
4. why incidence differs betwixt populations (the progressive antibody cistron is much communal successful group of European ancestry) and
5. why galore cases occurred aft a first vaccine dose (it stems from boosting pre‑existing anti‑pVII immunity from debased baseline antibody levels).

Just arsenic importantly, nan find provides a applicable roadmap for vaccine developers to creation moreover safer vaccines without losing nan world advantages of adenoviral vaccine technology.

McMaster's domiciled successful nan discovery

Over nan people of 5 years, Warkentin has played a cardinal domiciled successful unraveling VITT, contributing cardinal insights astatine each step. In 2021, he co‑authored nan first insubstantial that identified nan syndrome. In 2023, he led nan first study showing that earthy adenovirus infection tin trigger nan aforesaid PF4‑reactive antibodies, a pivotal uncovering that pointed researchers toward adenovirus arsenic nan underlying cause. In 2024, he helped uncover that vaccine‑ and virus‑induced cases stock an identical antibody "fingerprint." In 2025, he led a study that expanded nan objective spectrum of humor clotting linked to VITT-like antibodies. These insights helped group nan shape for nan caller NEJM study, which pinpoints pVII and nan K31E mutation arsenic nan mechanism.

Study activity and support

The investigation was led by Jing Jing Wang and Tom Gordon (Flinders University, Australia), Linda Schönborn, Luisa Müller, and Andreas Greinacher (Universitätsmedizin Greifswald, Germany), and Theodore E. Warkentin (McMaster University, Canada), pinch contributions from world partners.

The study was supported by nan American Society of Hematology (Global Research Award), Competence Center for Genomic Analysis (Kiel), Deutsche Forschungsgemeinschaft (DFG), DFG Research Infrastructure Next Generation Sequencing (NGS) Competence Center / NGS Competence Network, Else Kröner‑Fresenius Stiftung, European Medicines Agency, Flinders Foundation (Health Seed Grant), Gates Foundation, National Health and Medical Research Council (Ideas Grant) and Universitätsmedizin Greifswald (Gerhard Domagk Research Program).